Tecentriq 1,200 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FHNT9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,733
Award facts
- Contract value 100% obligated
- $20,733.33 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $20,733.33 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Tecentriq (1,200 mg/20 mL vial). The delivery order, issued on January 5, 2026, with an ultimate completion date of January 27, 2026, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors for pharmaceutical supply to Department of Defense healthcare facilities worldwide.
The PPV-G GEN V contract, valued at $499,999,999 with a completion date of December 31, 2036, authorizes DLA to issue delivery orders for a comprehensive range of pharmaceuticals including branded and generic prescription drugs, biologics, and medical consumables to support military healthcare operations globally. Tecentriq, an oncology treatment, falls within DMS Pharmaceutical Group's established product portfolio of specialty pharmaceuticals and cancer medications supplied to federal military medical facilities. The vendor's demonstrated performance across numerous delivery orders positions it as a critical supplier within the federal pharmaceutical supply chain serving the Department of Defense.
Quick answers
Who was awarded contract SPE2DR26FHNT9?
SPE2DR26FHNT9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26FHNT9 worth?
The government has obligated $20,733 on SPE2DR26FHNT9.
Is contract SPE2DR26FHNT9 an order under another contract?
Yes. SPE2DR26FHNT9 is a delivery order under SPE2DR25D9231, an indefinite delivery contract.
Was contract SPE2DR26FHNT9 competed?
The extent of competition for SPE2DR26FHNT9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award